You are here: Home » PTI Stories » National » News
Business Standard

Panacea Biotec gets EIR from USFDA for its Baddi facility

Press Trust of India  |  New Delhi 

Drug firm today said it has received Establishment Inspection Report (EIR) from the US regulator for its in

The company has received from the Food & Drug Administration (USFDA) indicating the formal closure of the inspection conducted by it, at the company's for oncology parenteral and oral solids dosage at Baddi, said in a filing to BSE.

Commenting on the development, Joint MD said: "This notification again demonstrates the company's ability to produce drugs in cGMP compliant environment in a sustainable manner."

The company remains committed to continue to manufacture and to cater to patients' needs across several markets including USA, he added.

As per the USFDA, after the completion of an inspection of a facility, an is issued to a company detailing inspectional findings.

Shares of Panacea Biotec today closed at Rs 281.05 per scrip on BSE, down 0.05 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, March 09 2018. 17:35 IST